Global regulators are increasing their watch on antitrust issues, pricing issues, IP, patent laws, etc. China’s regulators are doing the same and earlier this year issued 2 policy reports – The Fourteenth Five Year Modernization of Market Regulation Plan and the Fourteenth Five Year Pharmaceutical Industry Plan. These reports focus on drug enforcement of high pricing, supply limitations, exclusive dealing, etc. As a result, the State Administration for Market Regulation (SAMR) has issued many fines, primarily to domestic drug manufacturers, for these types of infractions. Similar fines are expected to increase on Western drug companies in China and several months ago, the SAMR fined a local division of a Swiss drug company about $1.5 million dollars for unfair price manipulation.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.
Source used in the article: https://www.davispolk.com/insights/client-update/china-antitrust-review-2021